Hostname: page-component-745bb68f8f-grxwn Total loading time: 0 Render date: 2025-01-18T19:31:18.009Z Has data issue: false hasContentIssue false
  • English
  • Français

Taking the Next Steps in the Treatment of Alzheimer's Disease: Disease-Modifying Agents

Published online by Cambridge University Press:  07 November 2014

Stephen Salloway
Get access Rights & Permissions [Opens in a new window]

Extract

Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder in the United States and the number of AD patients is increasing at an alarming rate. There is no cure for AD and the currently available treatments are symptomatic, providing only limited effects on disease pathophysiology and progression. An overwhelming need exists for therapies that can slow or halt this debilitating disease process. Disease modification in AD has been defined from patient-focused, regulatory, and neurobiological perspectives. The latter two of these perspectives rely largely on an interruption of the disease process and a clear demonstration of this interruption. As defined by Cummings, a disease-modifying treatment is a “pharmacologic treatment that retards the underlying process of AD by intervening in the neurobiological processes that constitute the pathology and pathophysiology of the disease and lead to cell death or dysfunction.” By this definition, the burden of confirmatory study is placed on any new treatment for which the claim of “disease modification” is to be made (Slide 1).

Type
Expert Review Supplement
Information
CNS Spectrums , Volume 13 , Issue S3: Next Steps in Alzheimer's Disease: Improvements in Diagnosis and Treatment , March 2008 , pp. 11 - 14
Copyright
Copyright © Cambridge University Press 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Sampaio, C. Alzheimer disease: disease modifying trials; where are we? Where do we need to go? A reflective paper. J Nutr Health Aging. 2006;10(2):113–115.Google Scholar
2.Mani, RB. The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint. Stat Med. 2004;23(2):305–314.Google Scholar
3.Cummings, JL. Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials. Alzheimers Dement. 2006;2(4):263–271.CrossRefGoogle ScholarPubMed
4.Games, D, Adams, D, Alessandrini, R, et, al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature. 1995;373(6514):523–527.Google Scholar
5.Holcomb, L.Gordon, MN, McGowan, E, et al.Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med. 1998;4(1):97–100.Google Scholar
6.Lewis, PA, Piper, S, Baker, M, et al.Expression of BRI–amyloid β peptide fusion proteins: a novel method for specific high-level expression of amyloid β peptides. Biochim Biophys Acta. 2001;1537(1):58–62.Google Scholar
7.Lewis, J, McGowan, E, Rockwood, J, et al.Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet. 2000;25(4):402–405.Google Scholar
8.Oddo, S, Caccamo, A, Shepherd, JD, et al.Triple-transgenic model of Alzheimer's disease with plaques and tangles: intraceliular Aβ and synaptic dysfunction. Neuron. 2003;39(3):409–421.Google Scholar
9.Golde, TE. The Aβ hypothesis: leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease. Brain Pathol. 2005;15(1):84–87.Google Scholar
10.Cummings, JL, Cole, G. Alzheimer disease. JAMA. 2002;287(18):2335–2338.Google Scholar
11.Zhu, CW, Scarmeas, N, Torgan, R, et al.Longitudinal study of effects of patient characteristics on direct costs in Alzheimer disease. Neurology. 2006;67(6):998–1005.Google Scholar
12.Zhu, CW, Scarmeas, N, Torgan, R, et al.Clinical features associated with costs in early AD: baseline data from the Predictors Study. Neurology. 2006;66(7):1021–1028.Google Scholar
13.Brookmeyer, R, Gray, S, Kawas, C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88(9):1337–1342.Google Scholar
14.Pollack, SJ, Lewis, H. Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease. Curr Opin Investig Drugs. 2005;6(1):35–47.Google Scholar
15.Wong, GT, Manfra, D, Poulet, FM, et al.Chronic treatment with the γ-secretase inhibitor LY-411,575 inhibits β-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem. 2004;279(13):12876–12882.Google Scholar
16.Morihara, T, Chu, T, Ubeda, O, Beech, W, Cole, GM. Selective inhibition of Aβ42 production by NSAID R-enantiomers. J Neurochem. 2002;83(4):1009–1012.Google Scholar
17.Wilcock, GK, Black, SE, Haworth, J, et al.Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective Aβ42-lowering agent, in Alzheimer's disease (AD): results of a 12-month phase 2 trial and 1-year follow-on study. Alzheimers Dement. 2006;2(3 suppl 1):S81–S82.Google Scholar
18.Aisen, PS, Saumier, D, Briand, R, et al.A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease. Neurology. 2006;67(10):1757–1763.Google Scholar
19.Neurochem announces results from tramiprosate (ALZHEMED™) North American Phase III clinical trial. Laval, Quebec: Neurochem Inc.: August 26, 2007.Google Scholar
20.Transition Therapeutics announces completion of Phase I clinical studies with Alzheimer's disease drug candidate ELND-005/AZD-103. Toronto, Ontario: Transition Therapeutics Inc.; August 30, 2007.Google Scholar
21.Boche, D, Nicoll, JA, Weller, RO. Immunotherapy for Alzheimer's disease and other dementias. Curr Opin Neurol. 2005;18(6):720–725.Google Scholar
22.Schenk, D, Barbour, R, Dunn, W, et al.Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400(6740):173–177.Google Scholar
23.Bayer, AJ, Bullock, R, Jones, RW, et al.Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD. Neurology. 2005;64(1):94–101.Google Scholar
24.Hock, C, Konietzko, U, Streffer, JR, et al.Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron. 2003;38(4):547–554.Google Scholar
25.Nicoll, JAR, Wilkinson, D, Holmes, C, Steart, P, Markham, H, Weller, RO. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med. 2003;9(4):448–452.Google Scholar
26.Solomon, B. Intravenous immunoglobulin and Alzheimer's disease immunotherapy. Curr Opin Mol Ther. 2007;9(1):79–85.Google Scholar
27.Dodel, RC, Du, Y, Depboylu, C, et al.Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2004;75(10):1472–1474.Google Scholar
28.Pfizer and TransTech Pharma enter into agreement for the development and commercialization of RAGE modulators. New York, NY: Pfizer Inc.; September 18, 2006.Google Scholar
29.Geroldi, D, Falcone, C, Emanuele, E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem. 2006;13(17):1971–1978.Google Scholar
30.Lee, VM, Trojanowski, JQ. Neurodegenerative tauopathies: human disease and transgenic mouse models. Neuron. 1999;24(3):507–510.Google Scholar
31.Cole, G. A transgenic triple scores a home run. Nat Med. 2006;12(7):762–763.Google Scholar
32.Haroutunia, V, Davies, P, Vianna, C, Buxbaum, JD, Purohit, DP. Tau protein abnormalities associated with the progression of Alzheimer disease type dementia. Neurobiol Aging. 2007;28(1):1–7.Google Scholar
33.Hrnkova, M, Zilka, N, Minichova, Z, Koson, P, Novak, M. Neurodegeneration caused by expression of human truncated tau leads to progressive neurobehavioural impairment in transgenic rats. Brain Res. 2007;1130(1):206–213.CrossRefGoogle ScholarPubMed
34.Roberson, ED, Scearce-Levie, K, Palop, JJ, et al.Reducing endogenous tau ameliorates amyloid β–induced deficits in an Alzheimer's disease mouse model. Science. 2007;316(5825):750–754.Google Scholar
35.DeKosky, ST. Pathology and pathways of Alzheimer's disease with an update on new developments in treatment. J Am Geriatr Soc. 2003;51(5 suppl dementia):S314–S320.Google Scholar
36.Arnaud, L, Robakis, NK, Figueiredo-Pereira, ME. It may take inflammation, phosphorylation and ubiquitination to “tangle” in Alzheimer's disease. Neurodegener Dis. 2006;3(6”:313–319.CrossRefGoogle ScholarPubMed
37.Jick, H, Zornberg, GL, Jick, SS, Seshadri, S, Drachman, DA. Statins and the risk of dementia. Lancet. 2000;356(9242):1627–1631.Google Scholar
38.Fillit, HM. The role of hormone replacement therapy in the prevention of Alzheimer disease. Arch Intern Med. 2002;162(17):1934–1942.Google Scholar
39.Morris, MC, Evans, DA, Bienias, JL, et al.Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA. 2002;287(24):3230–3237.Google Scholar
40.Oken, BS, Storzbach, DM, Kaye, JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol. 1998;55(11):1409–1415.Google Scholar
41.Frank, B, Gupta, S. A review of antioxidants and Alzheimer's disease. Ann Clin Psychiatry. 2005;17(4):269–286.Google Scholar
42. in t' Veld, BA, Ruitenberg, A, Hofman, A, et al.Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med. 2001;345(21):1515–1521.Google Scholar
43.Nordberg, A, Hellström-Lindahl, E, Lee, M, et al.Chronic nicotine treatment reduces β-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw). J Neurochem. 2002;81(3):655–658.Google Scholar
44.Dickson, DW. Apoptotic mechanisms in Alzheimer neurofibrillary degeneration: cause or effect? J Clin Invest. 2004;114(1):23–27.Google Scholar
45.Lad, SP, Neet, KE, Mufson, EJ. Nerve growth factor: structure, function and therapeutic implications for Alzheimer's disease. Curr Drug Targets CNS Neurol Disord. 2003;2(5):315–334.Google Scholar
46.Tuszynski, MH, Thal, L, Pay, M, et al.A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med. 2005;11(5):551–555.Google Scholar
47.Pradines, A, Magazin, M, Schiltz, P, Le Fur, G, Caput, D, Ferrara, P. Evidence for nerve growth factor-potentiating activities of the nonpeptidic compound SR 57746A in PC12 cells. J Neurochem. 1995;64(5):1954–1964.CrossRefGoogle ScholarPubMed
48.Fournier, J, Boutot, G, Keane, PE, Maffrand, JP, Le Fur, G, Soubrié, P. The non-peptide neuroprotective agent SR 57746A interacts with neurotrophin-3 to induce differentiation in the PC12 cell-line. J Pharm Pharmacol. 1998;50(3):323–327.Google Scholar
49.Labie, C, Lafon, C, Marmouget, C, et al.Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex. Br J Pharmacol. 1999;127(1):139–144.Google Scholar
50.Fournier, J, Steinberg, R, Gauthier, T, et al.Protective effects of SR 57746A in central and peripheral models of neurodegenerative disorders in rodents and primates. Neuroscience. 1993;55(3):629–641.Google Scholar
51.Lemaire, L, Fournier, J, Ponthus, C, et al.Magnetic resonance imaging of the neuroprotective effect of xaliproden in rats. Invest Radiol. 2002;37(6):321–327.Google Scholar
52.Terranova, JP, Kan, JP, Storme, JJ, Perreaut, P, Le Fur, G, Soubrié, P. Administration of amyloid β-peptides in the rat medial septum causes memory deficits: reversal by SR 57746A, a non-peptide neurotrophic compound. Neurosci Lett. 1996;213(2):79–82.Google Scholar
53.18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type. Available at: http://clinicaltrials.gov/ct/show/NCT00103649. Accessed February 22, 2008.Google Scholar
54.A promising R&D portfolio, well positioned to deliver future growth. Paris, France: sanofi-aventis: September 17, 2007. Available at: http://en.sanofi-aventis.com/press/ppc_18851.asp#3. Accessed February 22, 2008.Google Scholar
55.Dubois, B, Feldman, HH, Jacova, C, et al.Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734–746.Google Scholar